First line palliative chemotherapy in elderly patients with advanced soft tissue sarcoma

Area of Science:

• Oncology
• Geriatric Medicine
• Pharmacology

Background:

• Efficacy and toxicity of first-line palliative chemotherapy for soft tissue sarcomas (STS) in elderly patients are not well-documented.
• Limited data exists on treatment outcomes for advanced STS in individuals over 65 years.

Purpose of the Study:

• To describe the efficacy and toxicity of first-line palliative chemotherapy for advanced soft tissue sarcomas in elderly patients.
• To identify predictive factors for survival in this patient cohort.

Main Methods:

• Retrospective analysis of 120 patients aged 65 years and older with advanced non-GIST STS treated between January 1998 and January 2012.
• Data collected included patient demographics, tumor characteristics, treatment details, survival outcomes, and toxicity events.

Main Results:

• Median overall survival was 6.5 months. Common subtypes included undifferentiated sarcoma, leiomyosarcoma, and angiosarcoma; 70% had metastatic disease.
• Partial response or stable disease was observed in 40% of patients. 38% required hospitalization due to chemotherapy-related toxicity.
• Predictive factors for overall survival included anemia, lymphopenia, hypoalbuminemia, sarcoma subtype, and comorbidities.

Conclusions:

• Elderly patients with STS have poor overall survival, but several predictive factors for survival have been identified.
• Hospital admissions due to chemotherapy-related toxicity are frequent in this population, highlighting the need for careful management.